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Abstract 
 
 
 Coadministration of entacapone with levodopa attenuates motor complications in 
experimental models of Parkinson’s disease. The mechanisms underlying entacapone 
effects are unknown. We investigated the effect of entacapone, on: long duration response 
(LDR) to levodopa, levodopa-induced postsynaptic pharmacodynamic mechanisms and 
molecular changes in hemiparkinsonian rats. 6-hydroxydopamine-unilaterally lesion rats 
were treated with levodopa (25 mg /kg)+vehicle; levodopa+entacapone (30 mg/kg) or 
saline, twice daily for 22 days. The LDR and the apomorphine-induced rotations were 
measured. In situ hybridization was performed measuring the expression of striatal 
preproenkephalin, preprodynorphin and dopamine D-3 receptors mRNAs, subthalamic 
cytochrome oxidase mRNA and nigral glutamic acid decarboxylase mRNA. Entacapone 
potentiated the LDR but did no modify neither the apomorphine-induced rotational 
behavior nor the molecular changes. Our results suggest that the effects of entacapone on 
levodopa-induced motor response are no mediated by postsynaptic mechanisms and that 
administration of entacapone is not able to normalize the molecular alterations induced by 
levodopa in the basal ganglia. 
 
 
 
 
Keywords: Parkinson’s disease, levodopa, entacapone. 6-hydroxydopamine, preproenkephalin, 
preprodynorphin 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
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Under physiological circumstances, extra-synaptic striatal dopamine (DA) levels are 
relatively constant and DA receptors are stimulated in a relatively continuous manner 
(Abercrombie et al. 1990; Floresco et al. 2003; Venton et al. 2003). In Parkinson’s disease (PD), 
there is a loss of dopaminergic neurons and terminals and striatal DA levels are increasingly 
dependent on the peripheral availability of levodopa (Abercrombie et al. 1990; Miller and 
Abercrombie 1999; de la Fuente-Fernandez et al. 2004). Therefore, in advanced PD the 
fluctuations in plasma levels of short-acting dopaminergic agents, such as levodopa, lead to 
alternating high and low levels of activation of striatal DA receptors. This “pulsatile” pattern of 
receptor stimulation is a function of both, disease severity (Bedard et al. 1986; Pearce et al. 1998, 
2001; Jenner 2000) and the short half-life of the dopaminergic agent employed (Bedard et al. 
1986; Nutt 1990; Pearce et al. 1998; Olanow and Obeso 2000; Olanow et al. 2006). Sustained 
evidence has been accumulated indicating that levodopa-related motor complications in PD are 
associated with non-physiological, intermittent or pulsatile stimulation of striatal DA receptors 
(Chase et al. 1989, 1994; Juncos et al. 1989; Blanchet et al. 1995; Grondin et al. 1996; Stocchi 
and Olanow 2004; Olanow et al. 2006; Fabbrini et al. 2007). 
This concept suggests that a more continuous stimulation of DA receptors may ameliorate 
or even reduce the development of motor complications. The former has been shown in PD (Quinn 
et al. 1984; Obeso et al. 1986; Mouradian et al. 1990; Nutt 1990; Olanow et al. 2006; Nyholm 
2007) and the latter in experimental parkinsonism (Bedard et al. 1986; Blanchet et al. 1995; 
Grondin et al. 1996; Pearce et al. 1998; Maratos et al. 2001; Jenner 2004; Smith et al. 2005; 
Nyholm 2007). The concept of continuous dopaminergic stimulation (CDS) is supported by a 
wealth of experimental data showing that the dopaminergic system exerts a dual (tonic and phasic) 
effect on the striatum (Grace 1991; Floresco et al. 2003). In patients with PD, clinical 
pharmacological studies also support the therapeutical concept of CDS (Chase et al. 1989, Obeso 
et al. 1994, 2000; Olanow and Obeso 2000; Olanow et al., 2006). 
There is evidence suggesting that pulsatile striatal stimulation induce postsynaptic 
pharmacodynamic mechanisms which result in altered regulation of striatal genes and proteins, 
which ultimately leads to abnormal neuronal firing patterns in the striatopallidal circuitries 
(Herrero et al. 1995; Jolkkonen et al. 1995; Morissette et al. 1997, 1999; Olanow and Obeso 2000; 
Aubert et al. 2005; Gardoni et al. 2006; Bychkov et al. 2007). In more detail, chronic levodopa or 
dopamine agonist treatment elevates the expression of the striatal enkephalin precursor 
preproenkephalin (PPE), the opioid peptide expressed in the striatal neurons that project to the pars 
externa of the globus pallidus (GPe), above the levels reached after DA denervation alone (Gerfen 
et al. 1990; Herrero et al. 1995; Henry et al. 1999; Ravenscroft et al. 2004; Chen et al. 2005). 
Moreover, a significant correlation has been found between levodopa-induced complications and 
increased striatal levels of preprodynorphin (PDyn) mRNA, the opioid peptide expressed in the 
striatal neurons that project directly to the output structures of the basal ganglia, in a rodent model 
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of PD (Cenci et al. 1998; Andersson et al. 1999; Carta et al. 2002; Winkler et al. 2002; 
Ravenscroft et al. 2004). Levodopa-induced changes in striatal gene expression are believed to 
result form abnormal, intermittent stimulation of supersensitive receptors on DA-denervated 
striatum because PPE and PDyn mRNA changes can be normalized with long-acting DA agonists 
that do not induce dyskinesia (Henry et al. 1999; Calon et al. 2000) and when the same short 
acting-DA agonists are continuously administered (Morissette et al. 1997). 
Entacapone is a potent, selective and reversible peripherally acting inhibitor of catechol-O-
methyl transferase (COMT), the enzyme that provides the main breakdown pathway for levodopa 
in the blood after dopa decarboxylase. Inhibition of COMT by entacapone prolongs the half-life of 
levodopa (Nutt et al. 1994; Ruottinen and Rinne 1996) and this is associated with improved 
clinical efficacy in PD patients (Kaakkola and Wurtman 1993; Nutt et al. 1994; Ruottinen and 
Rinne 1996; Parkinson Study Group 1997; Rinne 1998; Poewe 2002, Stocchi et al. 2004; Grandas 
et al. 2007; Deuschl et al. 2007; Müller et al. 2007) and in experimental models of parkinsonism  
(Smith et al. 2003; 2005; Marin et al. 2005, 2006). By extending the half-life of levodopa with 
entacapone, it is possible to deliver the drug in a way that is less pulsatile, thereby allowing the 
benefit of levodopa with a reduced risk for motor complications. In detail, the administration of 
entacapone attenuates and prevents the development of levodopa-induced motor fluctuations 
(Marin et al. 2005) and dyskinesias in 6-OHDA-lesioned rats (Marin et al. 2006) and in MPTP-
treated monkeys (Smith et al. 2003, 2005). However, it is still unknown whether the 
administration of entacapone modifies the molecular changes induced by levodopa in the basal 
ganglia nuclei. 
The motor response to levodopa is comprised of two components: the long duration 
response (LDR) and the short duration response (SDR) (Muenter and Tuce 1971). The SDR is 
characterized by a short-lasting motor improvement typically lasting 3-4 h following a single dose 
of levodopa. The SDR is the basis for the clinical phenomenon of the motor fluctuation known as 
“wearing-off”. However, the LDR is a sustained motor improvement that takes days to build up 
and lasts for many hours to days after levodopa discontinuation (Nutt et al. 1995; Quattrone et al. 
1995; Zappia et al. 1997). A study in the novo patients (the ELLDOPA trial) has shown that the 
LDR may actually last for several weeks after cessation of levodopa treatment (Parkinson Study 
Group 2004). An experimental model of the LDR to levodopa has been recently described in 6-
OHDA-lesioned rats (Marin et al. 2007). An improvement in forelimb akinesia that lasted for at 
least 2 days after levodopa discontinuation resembling the LDR to levodopa in patients, has been 
observed (Marin et al., 2007). The effect of entacapone on the LDR to levodopa is still unkonwn.  
Based in the hypothesis that entacapone may provide a greater bioavailability of levodopa 
in the brain and thus, a more continuous stimulation of dopaminergic receptors, we investigated  if 
entacapone administration  normalizes the molecular alterations induced by levodopa treatment. 
We tried to define in more detail the mechanism of action by which levodopa plus entacapone 
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administration reduces motor complications in the 6-OHDA rat model by assessing  The effect of 
entacapone on: (i) the LDR to levodopa, (ii) the postsynaptic pharmacodynamic mechanisms 
induced by levodopa, and (iii) the levodopa-induced molecular changes in the basal ganglia nuclei. 
A better definition of putative  postsynaptic mechanisms mediating  the entacapone effect may 
beclinical relevant as they may be  involved in the development or maintenace of levodopa-
induced motor complications and thus,  might  be avoided with future treatment strategies. 
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Material and Methods 
 
6-OHDA lesions 
 Forty-four male Sprague-Dawley rats weighing 220-240 g were housed on a 12-hour 
light/dark cycle with free access to food and water. Under sodium pentobarbital anesthesia (50 
mg/kg, intraperitoneal, i.p.), rats were placed in a stereotactic frame with the incisor bar positioned 
4.5 mm below the interaural line. Each animal received a 6-OHDA (Sigma, Spain) injection (8 µg 
in 4 µl of saline with 0.02% ascorbate over 8 minutes) into the left medial forebrain bundle by 
means of a Harvard infusion pump. Stereotactic injections were placed 4.0 mm anterior to the 
interaural line, 1.3 mm lateral to the midline and 8.4 mm ventral to the surface of the skull, 
according to the atlas of Paxinos and Watson (1986). Adequate measures were taken to minimize 
pain or discomfort. All animal experiments were carried out in accordance with the National 
Institutes of Health guide for care and use of laboratory animals and approved by the local 
Government. 
 
Protocol of treatments  
 Animals were distributed in three groups and treated with (1) levodopa methyl ester (25 
mg/kg with 6.25 mg/kg benserazide, i.p.) (Sigma, Spain) plus vehicle (n=16) twice a day; (2) 
levodopa methyl ester (25 mg/kg with 6.25 mg/kg benserazide, i.p.) plus entacapone (30 mg/kg, 
i.p., n= 18) twice a day, or vehicle  (n= 10 ) for 22 consecutive days.  
 
Experimental design 
 Three sets of experiments were performed in order to investigate the effect of chronic 
entacapone administration on: i) levodopa-induced LDR ii) levodopa-induced postsynaptic 
pharmacodynamic alterations and, iii) levodopa-induced molecular changes in the basal ganglia 
nuclei.  
 In the first set, the effect of chronic entacapone on levodopa-induced LDR was evaluated. 
The effect of entacapone on the use of the parkinsonian limb induced by levodopa was 
investigated by performing the cylinder test. LDR was investigated before and after a dose test of 
levodopa (6 mg/kg) in 6-OHDA-lesioned rats during and until 7 days after levodopa or levodopa 
plus entacapone chronic treatment (Marin et al. 2007).  
 In the second set of experiments, we evaluated whether postsynaptic pharmacodynamic 
mechanisms were involved in the entacapone effect on levodopa-induced motor response. The 
rotational response to apomorphine (0.5 mg/kg, sc) (Sigma, Spain) was evaluated 3 days after the 
last treatment day in both, levodopa plus vehicle and levodopa plus entacapone, treated animals. 
 And finally, to investigate the effects of entacapone on levodopa-induced molecular 
changes in the basal ganglia nuclei, groups of animals treated following the same protocol than for 
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the behavioral studies, were sacrificed after 3 days of washout and the in situ hybridization studies 
were performed.  
 
Rotational Screening 
 
 For the measurement of rotational behavior, rats were placed in circular cages and 
tethered to an automated rotometer. The number of complete (360º) turns made during each 5-
minute period was automatically recorded by a computerized system. Rats were allowed 15 
minutes to habituate to the rotometer before drug administration. Following a three-week recovery 
period, rats exhibiting a vigorous rotational response (>100 total turns) to apomorphine (0.05 
mg/kg, subcutaneous (sc) were selected for further study. It has been previously demonstrated that 
rats meeting this criterion have a greater than 95% depletion of striatal dopamine (Papa et al. 
1994). Apomorphine-induced rotations (0.5 mg/kg, sc) were measured to evaluate the involvement 
of postsynaptic mechanisms in entacapone effects. 
 
 Forelimb akinesia-Cylinder test 
 
To assess forelimb akinesia the cylinder test was used as previously described (Schallert et 
al. 2000; Marin et al. 2007). Rats were placed individually in a circular cylinder and the number of 
supporting well contacts that were carried out with each of the right (parkinsonian) and left 
forelimb was counted for a period of 5 min prior and 45 min after the administration of a test dose 
of levodopa (6 mg/kg). No habituation to the cylinder prior to testing was allowed. Forelimb 
akinesia was evaluated before and after 6-OHDA lesion, 3 days after and then weekly during 
levodopa or levodopa plus entacapone treatment, followed by evaluations at 4h, 2, 5 and 7 days 
after levodopa or levodopa plus entacapone withdrawal. 
 
Tissue collection 
 
Three days after last levodopa, levodopa plus entacapone or saline administration rats were 
sacrificed under an overdose of pentobarbital anaesthesia. Brains were quickly removed from the 
skull and then frozen on dry ice and kept at -80ºC until were cut on a cryostat. Coronal 14 µm 
thick sections were collected through the striatum onto APTS (3-amino-propyltriethoxysilane) 
coated slides, and kept at -40ºC until used.  
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     Dopamine transporter (DAT) immunohistochemistry 
 
Striatal sections were thawed and dried at room temperature and fixed with acetone for 10 
min at 4ºC. The sections were rinsed in PBS (phosphate buffered saline, pH 7.4) twice, 5 min 
each, and immersed in 0.3% hydrogen peroxide in PBS for 10 min to block the endogenous 
peroxidase. At this point, sections were rinsed again in PBS and incubated with horse serum with 
0.1% Triton X-100 for 20 min. Sections were incubated overnight at 4ºC with mouse anti-DAT 
monoclonal antibody (SantaCruz Biotechnology, Spain) at a dilution 1:500 in PBS. Sections were 
rinsed twice in PBS, 5 min each, and ImmunoPure Ultra-Sensitive ABC Peroxidase staining kit 
(Pearce, Spain) was used to carry out the ABC staining method. By so doing, sections were 
incubated with biotinylated horse anti-mouse Ig-G for 30 min, followed by two rinses in PBS, and 
then incubated with avidin-biotinylated peroxidase complex for 30 min more. Finally, sections 
were rinsed in PBS and incubated with 3-3’-diaminobenzidine and 0.01% hydrogen peroxide for 
15 min. Slides were washed with PBS, dehydrated in ascending alcohol concentrations, cleared in 
xylene and coverslipped in DPX-EXLI mounting medium.  
 
In situ hybridization histochemistry 
 
The oligonucleotides used were complementary to the following base sequences 
(GeneBank accession number in brackets): preprodynorphin, bases 607-654 [NM_019374]; 
preproenkephalin, bases 513-542 [K02807]; cytochrome oxidase subunit I, bases 644-688 
[S79304]; glutamic acid decarboxylase 67 (GAD67), bases 191-235 and 1600-1653 [NM_01700]; 
dopamine D3 receptors, bases 85-132, 1144-1191 and 1381-1426 [NM_017140]. They were 
synthesized and HPLIC purified by Amersham Pharmacia Biotech (UK) and by Isogen Bioscience 
BV (Maarsden, The Netherlands). The oligonucleotides were labeled at their 3’-end by using 
[33P]dATP (3000 Ci/mmol, New England Nuclear, Boston, MA, USA) and terminal 
deoxynucleotidyl-transferase (TdT, Oncogene Research Products, San Diego, CA, USA), and 
purified using QIAquick Nucleotide Removal Kit (QIAGEN GmbH, Hilden, Germany). 
For in situ hybridization, frozen tissue striatal sections were brought to room temperature, 
air-dried, and fixed for 20 min in 4% paraformaldeyde in phosphate-buffered saline (1 x PBS: 2.6 
mM KCl, 1.4 mM KH2PO4, 136 mM NaCl,  8 mM Na2HPO4), washed once in 3 x PBS, twice in 1 
x PBS, 5 min each, and incubated in a freshly prepared solution of predigested pronase at a final 
concentration of 24 U/ml in 50 mM Tris-HCl pH 7.5, 5 mM EDTA. The enzymatic activity was 
stopped by immersion for 30 sec in 2mg/ml glycine in 1x PBS. Tissues were finally rinsed in 1x 
PBS and dehydrated through a graded series of ethanol. For hybridization, radioactively-labeled 
probes were diluted to a final concentration of 107 cpm/ml in a solution containing 50% 
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formamide, 4x SSC (1x SSC: 150 mM NaCl, 15 mM sodium citrate), 1x Denhardt’s solution 
(0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% bovine serum albumin), 10% dextran sulfate, 
1% sarkosyl, 20 mM phosphate buffer pH 7.0, 250 µg/ml yeast tRNA and 500 µg/ml salmon 
sperm DNA. Tissues were covered with 100 µl of the hybridization solution and overlaid with 
Nescofilm (Bando Chemical, Kobe, Japan) coverslips to prevent evaporation. Sections were 
incubated in humid boxes overnight at 42 ºC and then washed 4 times (45 min each) in 600 mM 
NaCl, 20 mM Tris-HCl, pH 7.5, 1 mM EDTA at 60 ºC. Hybridized sections were exposed to 
BIOMAX-MR film (Kodak) for 1 day to five days depending on the probe used at -70ºC with 
intensifying screens.  
The specificity of the nucleotide hybridization signals was assessed as follows. For a given 
oligonucleotide probe the presence of a 50-fold excess of the same unlabeled oligonucleotide in 
the hybridization buffer resulted in the abolishment of the specific hybridization signal (data not 
shown). The thermal stability of the hybrids was examined by washing a series of consecutive 
hybridized sections at increasing temperatures. Specific hybridization signals were still present in 
sections washed at 70 ºC but they were completely absent from sections washed at 80 ºC. No such 
decrease was observed in the background levels of the signal (data not shown).  
The average densities of the mRNAs in different brain regions were evaluated semi 
quantitatively on film autoradiograms with the aid of an image analysis system (MCID M4, 
Imaging Research, St Catherines, Ontario, Canada).  
Hybridized tissue section images from film autoradiograms were photographed with a 
digital camera (DXM1200 F, Nikon) and ACT-1 Nikon Software using a Wild makroscope M-
420. Figures were prepared for publication using Adobe Photoshop software (Adobe Software, 
San Jose, CA, USA). Contrast and brightness of images were the only variables we adjusted 
digitally. For anatomical reference, sections close to those used were stained with Cresyl violet. 
 
Statistics 
 Data were analyzed by analysis of variance (ANOVA) followed by Dunnett’s t-test 
for multiple comparisons or paired Student t-test when required. The level of statistical 
significance was set at p<0.05 for all analyses. 
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Results 
 
Characterization of the unilateral 6-OHDA lesion 
 
 Rats with a complete 6-OHDA lesion exhibited a rotational response to apomorphine 
injection (>100 rotations). A quantitative analysis showed an absence of dopamine 
transporter (DAT)-immunoreactivity in the ipsilateral striatum (Figure 1). No significant 
differences in the degree of dopaminergic denervation were observed among the groups of 
rats that received levodopa, levodopa plus entacapone or saline administration (Figure 1). 
 
Effects of chronic administration of levodopa plus entacapone on forelimb akinesia 
 
 Prior to 6-OHDA lesion, the proportion of wall contacts performed with the right paw 
amounted to 55% and 52% of total in levodopa and levodopa plus entacapone-treated 
animals, respectively. This percentage of wall contacts with the right (parkinsonian) paw 
was minimal 3 weeks after 6-OHDA lesion in all animals (p<0.01) (Figure 2). 
During levodopa (25 mg/kg with 6.25 mg/kg benserazide) or levodopa plus 
entacapone (30 mg/kg) treatment, the limb asymmetry was measured 45 minutes after a test 
dose of levodopa (6 mg/kg), (Figure 2). Forelimb akinesia was evaluated before and after 6-
OHDA lesion, 3 days after and then weekly during levodopa or levodopa plus entacapone 
treatment, followed by evaluations at 4h, 2, 5 and 7 days after levodopa or levodopa plus 
entacapone withdrawal. A similar significant improvement in limb use asymmetry was 
observed in both group of animals chronically treated with levodopa or levodopa plus 
entacapone. This effect reached similar percentages of wall contacts than the ones achieved 
by the same limb prior to 6-OHDA lesion. The benefit lasted for several days. The increased 
limb activity in the levodopa-treated group was significant up to 48 h after levodopa 
treatment withdrawal, as previously reported (Marin et al. 2007) (Figure 2). In the group 
treated with levodopa plus entacapone the benefit lasted for 7 days after treatment 
withdrawal. 
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       Effects of chronic administration of levodopa plus entacapone on apomorphine-induced                  
rotational behavior 
 
 No differences were observed in the total number of contralateral rotations induced by 
apomorphine between both levodopa and levodopa plus entacapone treated groups (Figure 
3a). The administration of entacapone did not decrease the maximal peak of rotation 
induced by apomorphine and the duration of the rotational behavior was not significantly 
modified (Figure 3b). 
 
Effects of chronic administration of levodopa plus entacapone on molecular markers in 
basal ganglia 
 
Striatal PPE mRNA expression  
 
As expected, a significant increase in PPE mRNA levels in the lesioned striatum was observed 
after 6-OHDA lesion in the saline-treated animals compared with the intact striatum (p<0.01) 
(Figure 4). Levodopa treatment maintained the increase in striatal PPE levels (F2,11: 3.04)). In the 
group of animals treated with levodopa plus entacapone, the PPE mRNA levels did not differ from 
the ones achieved by levodopa treatment (Figure 4). PPE mRNA expression levels were not 
modified in the intact striatum of any group.  
 
Striatal PDyn mRNA expression 
 
 Striatal PDyn mRNA levels were significantly reduced in the 6-OHDA- lesioned striatum 
(p<0.01) in the saline-treated animals compared with the intact striatum, as expected (Figure 5). 
Levodopa treatment induced a significant increase in PDyn mRNA in the lesioned striatum in 
comparison with saline-treated rats (p<0.01) (F2,13: 27.53) and with intact side (p<0.05). In the 
group of animals treated with levodopa plus entacapone, the PDyn mRNA levels did not differ 
from the ones achieved by levodopa treatment (Figure 5). There were no significant changes in 
PDyn mRNA expression levels in the intact side in any group. 
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Striatal dopamine D-3 receptor mRNA expression 
 
Dopamine D-3 receptor mRNA expression was not modified by the 6-OHDA lesion 
compared with the intact striatum (Figure 6). Rats that received chronic intermittent treatment with 
levodopa showed a significant increase in DA D-3 mRNA in the lesioned striatum in comparison 
with the intact side (p<0.01) (F2,12: 2.83). In the group of animals treated with levodopa plus 
entacapone, the D-3 mRNA levels did not differ from the ones achieved by levodopa treatment 
(Figure 6) There were no significant changes in DA D-3 mRNA expression levels in the intact side 
in any group.  
 
Subthalamic cytochrome oxidase (CO) mRNA expression 
 
 Unilateral 6-OHDA lesion induced a significant increase in CO mRNA expression in the 
ipsilateral subthalamic nucleus (p<0.05) (Figure 7). Rats that received chronic intermittent 
treatment with levodopa showed a significant decrease in CO mRNA in the STN in comparison 
with saline-treated rats (p<0.05) (F2,13: 4.28). This effect was noticeable as the levels were 
normalized in comparison with the intact side in the same group. In the group of animals treated 
with levodopa plus entacapone, the subthalamic CO mRNA levels did not differ from the ones 
achieved by levodopa treatment (Figure 7). There were no significant changes in CO mRNA 
expression levels in the STN contralateral to the lesion. 
 
Nigral GAD mRNA expression 
 
Unilateral 6-OHDA lesion induced a significant increase in GAD67 mRNA expression in 
the ipsilateral pars reticulata of the substantia nigra (p<0.05) (Figure 8). Rats that received chronic 
intermittent treatment with levodopa showed a significant decrease in GAD67 mRNA in the 
ipsilateral SNr in comparison with saline-treated rats (p<0.05) (F2,13: 3.22). In the group of animals 
treated with levodopa plus entacapone, the nigral GAD67 mRNA levels did not differ from the ones 
achieved by levodopa treatment (Figure 8). There were no significant changes in GAD67 mRNA 
expression levels in the SNr contralateral to the lesion. 
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Discussion 
 
 Our present results show that the administration of entacapone increased the LDR 
induced by levodopa since in the 6-OHDA-lesioned rats treated with levodopa plus 
entacapone the beneficial motoric effect lasted for, at least, 7 days after treatment 
discontinuation. In the present study, we used a sub-threshold dose of levodopa as a test to 
evaluate the LDR to levodopa in animals chronically treated with a higher dose of 
levodopa, as previously described (Marin et al. 2007). Using such paradigm, we have 
observed an improvement in forelimb akinesia that lasted for, at least, 2 days after levodopa 
discontinuation (Marin et al. 2007). The phenomenology of this improvement and its 
further decay when levodopa is stopped resemble the LDR to levodopa. The potentiation of 
the LDR to levodopa by entacapone administration agrees with previous observations 
showing that entacapone attenuates and prevents levodopa-induced motor fluctuations in 6-
OHDA-lesioned rats (Marin et al. 2005) and PD patients (Parkinson Study Group 1997; 
Rinne et al. 1998; Reichmann et al. 2005; Grandas et al. 2007). In addition, a beneficial 
effect of entacapone administration attenuating levodopa or DA agonist-induced 
dyskinesias in 6-OHDA-lesioned rats (Marin et al. 2006) and in MPTP-treated monkeys 
(Smith et al. 2003, 2005, Zubair et al. 2007) has been already shown. Because it has been 
associated with levodopa, a presynaptic mechanism has been considered as one of the 
mechanisms involved in the LDR (Quattrone et al. 1995; Nutt and Holford 1996). 
However, a LDR can be produced in the novo patients with the dopamine agonist 
apomorphine (Nutt and Carter 2000) suggesting the involvement of postsynaptic 
pharmacodynamic mechanisms.  
 To address the possible postsynaptic mechanisms involved in the entacapone 
effect on levodopa-induced motor responses, we have measured the rotations induced by 
apomorphine 3 days after last treatment administration (Juncos et al. 1989). The action of 
apomorphine is mediated through postsynaptic D1 and D2 receptors and is not dependent of 
presynaptic mechanisms as occurs with levodopa. Juncos et al. (1989) found that 
continuous levodopa administration attenuated the increased rotational behavior response to 
apomorphine induced after intermittent administration indicating that the postsynaptic 
mechanisms involved in the motor effects after pulsatile stimulation of DA receptors were 
attenuated by the continuous administration of levodopa. In the present study, we show that 
coadministration of entacapone did not modify the rotational response to apomorphine in 
comparison with the one elicited by levodopa alone. This result suggests that postsynaptic 
mechanisms might not be involved in the entacapone effects on levodopa-induced motor 
responses such as LDR  
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 Abundant experimental evidence indicates that discontinous dopaminergic 
stimulation leads to dysregulation of genes and proteins in the basal ganglia nuclei in PD 
animal models , that in turn may lead to abnormal neuronal firing patterns that have been 
associated with dyskinesia in PD (Morissette et al. 1997; Vitek and Giroux 2000; Levy et al. 
2001; Aubert et al. 2005; Alonso-Frech et al. 2006). Neither, the gene changes nor the 
dyskinesia associated with a short–acting dopaminergic drug are reported when the same 
drug is given by continuous infusion (Morissette et al. 1997). In detail, the enkephalin 
precursor PPE mRNA is co-expressed with gammaaminobutyric acid (GABA)-striatal D-2 
bearing neurons and levels of PPE mRNA are upregulated after a DA lesion (Gerfen et al. 
1990; Jolkkonen et al. 1995; Morissette et al. 1997; Henry et al. 1999; Bezard et al. 2001; 
Ravenscroft et al. 2004; Marin et al. 2007). In 6-OHDA-lesioned rats, repeated 
administration of levodopa elicits and enhanced behavioral response that is associated with 
an increased striatal PPE mRNA expression (Ravenscroft et al. 2004; Chen et al. 2005; 
Marin et al. 2007). However, following repeated administration of antiparkinsonian agents 
with longer half-life such as bromocriptine,  which does not cause  behavioral enhancement,  
PPE mRNA expression is not increased (Henry et al. 1999). In MPTP monkeys, intermittent 
levodopa administration induces dyskinesia in association with persistent or even further 
upregulation of striatal PPE (Jolkkonen et al. 1995; Morissette et al. 1997, 1999). In 
contrast, long-acting dopamine agonists do not induce dyskinesia, and PPE levels are down-
regulated (Morissette et al. 1999). Moreover, when dyskinesias are induced by intermittent 
delivery of short-acting DA agonists, PPE levels remain up-regulated whereas when the 
same agonist is administered continuously, the animals do not experience dyskinesia and 
PPE levels are down-regulated (Morissette et al. 1997). On the other hand, PDyn mRNA 
that is expressed in the direct pathway is decreased in 6-OHDA lesioned rats (Henry et al. 
1999; Ravenscroft et al. 2004). Intermittent levodopa administration reverses, or further 
increases, the decrease in striatal PDyn mRNA (Andersson et al. 1999; Henry et al. 1999; 
Ravenscroft et al. 2004, Marin et al. 2007). However, long-acting drugs normalize the PDyn 
mRNA to pre-lesion levels (Henry et al. 1999).  
All of the above observations suggest that the motor improvement and the 
attenuation of motor complications-induced by the CDS are associated with a normalization 
of levodopa or DA agonist-induced molecular changes in the basal ganglia. From a 
theoretical point of view, provision of a constant supply of DA or a DA agonist to striatal 
DA receptors should mimic the state seen during normal tonic firing of dopaminergic 
receptors, by avoiding fluctuations in DA levels that accompany intermittent levodopa 
dosing and thus facilitate more normal control of movement (Olanow et al. 2006).  
A promising therapeutic strategy for PD focused on the potential of providing CDS 
to ameliorate or prevent levodopa-related motor complications have been developed using 
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COMT inhibitors such as entacapone (Fenelon et al. 2003; Deuschl et al. 2007; Grandas et 
al. 2007; Müller et al. 2007). Administration of a single dose of levodopa with a COMT 
inhibitor increases the levodopa plasma area under the curve and its elimination half-life 
without augmenting peak plasma levels (Nutt et al. 1994; Heikkinen et al. 2002). According 
to these pharmacokinetic features, the administration of levodopa with a COMT inhibitor 
could maintain more stable plasma levels, thus providing an increase in the bioavibility of 
levodopa and an increase in a longer duration of striatal DA receptor stimulation (Heikkinen 
et al. 2002; Gerlach et al. 2004; Paija et al. 2005). Until present, it was unknown whether 
the COMT inhibitor entacapone normalizes levodopa-induced molecular changes.  
Our present results show that the coadministration of entacapone with levodopa was 
not able to normalize levodopa-induced molecular changes in the basal ganglia nuclei. In 
detail, entacapone administration did not modify the increase in striatal PPE, PDyn or D-3 
mRNAs induced by levodopa. No significant differences were observed in CO mRNA in 
the subthalamic nucleus and in the GAD67 mRNA in the SNr between levodopa alone and 
levodopa plus entacapone groups. Altogether  these data indicates that the potentiation of 
the LDR to levodopa shown in the present study and the attenuation of levodopa-induced 
motor fluctuations and dyskinesias by entacapone previously reported (Marin et al. 2005, 
2006) are not related with a normalization of the molecular changes induced by levodopa in 
the basal ganglia nuclei. However, these observations do not contradict one to each other. 
The pharmacokinetics and pharmacodynamics of entacapone need to be taken in account. 
Microdialysis studies in rats showed that entacapone is able to enhance striatal DA output 
following administration of levodopa (Kaakola et al. 1993; Törnwall et al. 1994). The 
increased DA efflux produced by COMT inhibitors is thought to result from the higher brain 
availability of levodopa consequent to the reduced peripheral conversion of the amino acid 
into 3-O-methyl-DOPA (3-OMD). It has been shown that central COMT inhibitors in 
comparison with peripheral inhibitors, such as entacapone, have the additional capacity to 
further extend the half-life of levodopa being more effective than entacapone in increasing 
extracellular striatal levels of DA (Napolitano et al. 2003) and, thus, in stimulating the DA 
receptors in a more continuous manner.  
Thus, plasma levels of levodopa and consequent DA striatal concentrations 
achieved by administering levodopa plus benserazide plus entacapone twice daily are 
probably insufficient to achieve CDS and therefore, incapable to normalize levodopa-
induced molecular changes. Indeed, the half-life of entacapone might also be relevant to the 
lack of modification of levodopa-induced molecular alterations since it has been shown that 
is shorter than central COMT inhibitors (Forsberg et al. 2003).  Our findings as well as 
clinical pharmacokinetics studies (Stocchi et al. 2005) indicate that the triple combination of 
levodopa plus benserazide plus entacapone should be given several times per day (i.e. 4 
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times) in order to minimize the risks of developing motor complications. This has practical 
clinical implications in the designs of trials and for routine practice where levodopa plus 
benserazide plus entacapone is usually administered thrice a day. 
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Legends 
 
Figure 1. Representative DAT immunohistochemistry from 14 m coronal sections of the rostral 
striatum. Sections are from rats receiving 6-OHDA injection in the left forebrain bundle, and then 
treated for 22 days with (A) saline (n=10), (B) levodopa methyl ester (25 mg/kg with 6.25 mg/kg 
benserazide, i.p.) plus vehicle (n=16) twice a day, and (C) levodopa methyl ester (25 mg/kg with 
6.25 mg/kg benserazide, i.p.) plus entacapone (30 mg/kg, i.p., n= 18) twice a day. Note the 
significant absence of DAT immunoreactivity in the lesioned side regardless of the drug treatment. 
 
Figure 2. Long duration response to levodopa: Forelimb akinesia evaluated 45 minutes after a 
levodopa dose-test (6 mg/kg, i.p.) in unilateral 6-OHDA-lesioned rats chronically treated for 22 
days with levodopa methyl ester (25 mg/kg with 6.25 mg/kg benserazide, i.p.) plus vehicle twice a 
day, and levodopa methyl ester (25 mg/kg with 6.25 mg/kg benserazide, i.p.) plus entacapone (30 
mg/kg, i.p., twice a day. Values are expressed as mean ± SEM. ##p<0.01 vs before 6-OHDA; 
*p<0.05, **p<0.01 vs 22 days after 6-OHDA. 
 
Figure 3. Effect of entacapone on the postsynaptic mechanisms evaluated by means of 
apomorphine-induced rotational behaviour. The coadministration of entacapone (30 mg/kg, i.p., 
twice a day) did not modify the effect of levodopa on apormorphine-induced rotations; a) Total 
number of rotations; b) time- course curve. Values are expressed as mean ± SEM 
 
Figure 4. Striatal PPE mRNA expression in 6-OHDA-lesioned rats chronically treated treated for 
22 days with: levodopa methyl ester (25 mg/kg with 6.25 mg/kg benserazide, i.p.) plus vehicle 
twice a day; levodopa methyl ester (25 mg/kg with 6.25 mg/kg benserazide, i.p.) plus entacapone 
(30 mg/kg, i.p.) twice a day or saline. Upper: Values are expressed as mean ± SEM. **p<0.01 vs 
the corresponding intact side. Bottom: Representative film autoradiograms of coronal brain 
sections (14 µm) showing striatal PPE mRNA labelling in all treatment groups.  
 
Figure 5. Striatal PDyn mRNA expression in 6-OHDA-lesioned rats chronically treated for 22 
days with: levodopa methyl ester (25 mg/kg with 6.25 mg/kg benserazide, i.p.) plus vehicle twice 
a day; levodopa methyl ester (25 mg/kg with 6.25 mg/kg benserazide, i.p.) plus entacapone (30 
mg/kg, i.p.,) twice a day or saline. Upper: Values are expressed as mean ± SEM. *p<0.05, 
**p<0.01 vs the corresponding intact side; ++p<0.01 vs saline-treated animals. Bottom: 
Representative film autoradiograms of coronal brain sections (14 µm) showing striatal PDyn 
mRNA labelling in all treatment groups.  
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Figure 6. Striatal dopamine D-3 mRNA expression in 6-OHDA-lesioned rats chronically treated 
for 22 days with: levodopa methyl ester (25 mg/kg with 6.25 mg/kg benserazide, i.p.) plus vehicle 
twice a day; levodopa methyl ester (25 mg/kg with 6.25 mg/kg benserazide, i.p.) plus entacapone 
(30 mg/kg, i.p.,) twice a day or saline. Upper: Values are expressed as mean ± SEM. **p<0.01 vs 
the corresponding intact side. Bottom: Representative film autoradiograms of coronal brain 
sections (14 µm) showing striatal D-3 mRNA labelling in all treatment groups.  
 
Figure 7. Subthalamic CO mRNA expression in 6-OHDA-lesioned rats chronically treated for 22 
days with: levodopa methyl ester (25 mg/kg with 6.25 mg/kg benserazide, i.p.) plus vehicle twice 
a day; levodopa methyl ester (25 mg/kg with 6.25 mg/kg benserazide, i.p.) plus entacapone (30 
mg/kg, i.p.,) twice a day or saline. Upper: Values are expressed as mean ± SEM. *p<0.05 vs the 
corresponding intact side; #p<0.05 vs saline-treated animals. Bottom: Representative film 
autoradiograms of coronal brain sections (14 µm) showing subthalamic CO mRNA labelling in all 
treatment groups.  
 
Figure 8. GAD67 mRNA expression in the pars reticulata of the substantia nigra in 6-OHDA-
lesioned rats chronically treated for 22 days with: levodopa methyl ester (25 mg/kg with 6.25 
mg/kg benserazide, i.p.) plus vehicle twice a day; levodopa methyl ester (25 mg/kg with 6.25 
mg/kg benserazide, i.p.) plus entacapone (30 mg/kg, i.p.) twice a day or saline. Upper: Values are 
expressed as mean ± SEM. *p<0.05 vs the corresponding intact side; #p<0.05 vs saline-treated 
animals. Bottom: Representative film autoradiograms of coronal brain sections (14 µm) showing 
nigral GAD67 mRNA labelling in all treatment groups.  
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